ROCKLAND, Md. ~ September is a month of recognition for those suffering from Alzheimer's Disease (AD) and healthy aging. SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for AD, is advocating for the accurate identification of AD, implementing proactive risk reduction measures to delay and prevent the onset of AD and/or dementia, and promoting healthy cognitive aging.

The theme for World Alzheimer's Month 2023 is 'Never too early, never too late', which emphasizes the need for an early and accurate diagnosis of AD as well as recognizing risk factors. Frank Amato, CEO and President of SDx, stated that "World Alzheimer's Month is an important occasion to remember the suffering of individuals with cognitive loss and acknowledge the individuals who dedicate their energy, passion and careers to help patients and families." He also noted that up to 40% of dementia cases may be prevented by addressing modifiable risk factors such as physical inactivity, smoking, depression, mid-life hypertension, mid-life obesity and diabetes.

More on Marylandian

• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)

Amato also pointed out that treating hearing loss may be a safe way to lower the risk of dementia in vulnerable populations. Studies have shown that hearing aids reduced the rate of cognitive decline in older adults at higher risk of dementia by almost 50% over a three-year period.

SDx has developed DISCERN™ test - the first autopsy-validated skin test - to provide healthcare professionals with a diagnostic tool to accurately identify and distinguish AD from other forms of dementia even in presence of co-morbid pathologies. The minimally invasive 3mm skin punch biopsy can be administered in primary care setting. The sample is sent to SDx laboratory certified under Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing for analysis.

DISCERN assesses factors closely related to formation of synaptic connections in brain as well as formation of amyloid plaque and abnormal tau which are lost as cognitive functions decline even early in AD. It is recognized as world's only Gold Standard Validated benchmark offering such clinical insight and is first AD test paid for by Medicare. The autopsy-validated accuracy from simple procedure performed in clinicians office combined with positive economic modeling data positions DISCERN as key solution to reduce economic burden of AD across healthcare system while informing an early and accurate diagnosis - first step in assessing patients for therapeutic intervention.

---

Show All News | Report Violation